UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V.

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against uniQure N.V. regarding possible violations of federal securities laws and unlawful business practices following a significant drop in share price due to FDA concerns about the adequacy of data for a BLA submission [1][2]. Investigation Details - On November 3, 2025, uniQure announced that the FDA no longer believes that the data from Phase I/II studies of AMT-130 is sufficient for a BLA submission, leading to a share price decline of over 57% in morning trading on the same day [2]. Next Steps - Investors who purchased uniQure shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3]. About Bragar Eagel & Squire, P.C. - Bragar Eagel & Squire, P.C. is a law firm recognized nationally, representing individual and institutional investors in various types of litigation across state and federal courts [4].